To compare the prevalence and intensity of CD138 expression between tumor entities and to identify these cancer types that might be optimal candidates for anti-CD138 drugs, we thus analyzed more than 2500 cancers and 76 normal tissues using one standard protocol. Here, SDC1 is linked to neoplasm.